Because the product information summary exists to "supplement" the package insert, everything it contains must be grounded in approved facts. One word beyond the approved scope and the document is no longer a supplement — it is a deviation. Restrictive wording on indications, the ceiling on dosage, and the requirement for equal comprehensibility regardless of medium: these look like three separate rules, but they are all answers to the same question. "Can a healthcare professional understand the approved scope accurately from this material?"
Restrictive wording is not a footnote attached to an indication — it is a condition that defines the approval itself. Remove the condition and the shape of the approval changes. Likewise, the phrase "adjust as appropriate" in dosage instructions does not grant unlimited discretion; it allows adjustment within the upper and lower bounds that have been approved, nothing more. And whether the medium is paper or electronic, the quality of communication cannot be allowed to differ. All three rules are concrete consequences of what it means to supplement.
01Restrictive wording — reproducing the approval means copying the condition too
Some indications carry a condition on their use. "Only when [treatment X] is inappropriate," "patients for whom other therapeutic agents have been ineffective" — these phrases are restrictive wording.
Omitting restrictive wording rewrites the approval
What happens when an indication is written in the product information summary without its restrictive wording? The healthcare professional reading it concludes that the indication may be used without conditions. What the package insert approved conditionally appears in the material as unconditional. This is not a reproduction of the approval; it is an alteration of it.
The Guide's requirement that materials be written so that "the approved indication is communicated accurately, including any restrictive wording," follows directly from this. Restrictive wording is not appended to the indication; it is part of the definition of the indication. The same standard applies wherever the indication is mentioned — in the development history column, in the features column, anywhere. When indications differ between overseas and Japan, the domestic approved content must be stated separately, with restrictive wording intact.
Off-label indications — no statement, no suggestion
An unapproved indication may not be stated directly, and it may not be implied or hinted at. Labeling off-label trial results "reference information" does not change this; placed near the indication column, the boundary between approved and unapproved blurs for the reader. When off-label content must appear, the procedure is strict: state at the outset, in prominent text, that the content is partly off-label and give the reason for its inclusion, then annotate the corresponding approved indication and dosage.
The development history column and the features column allow a narrative — but what may be narrated is bounded by approved facts. If a drug is approved for a wider indication overseas, emphasizing that fact in a domestic document creates expectations about an unapproved use. The Guide's explicit requirement to write domestic and overseas content separately reflects exactly this risk.
02Dosage — "adjust as appropriate" is not a waiver of the ceiling
The same principle runs through dosage. Do not state anything outside the approved dosage range. The phrase most likely to be misread here is "adjust dosage as appropriate."
What "adjust as appropriate" means — and what it does not
When approved dosage instructions include "adjust as appropriate," this permits the prescriber to calibrate the dose to the patient's condition. But the room for adjustment lies within the range the approval document expressly specifies; it is not permission to exceed the stated ceiling. A product information summary may not present efficacy data from doses above the approved maximum, even when adjustment is permitted.
Trial data that are inconsistent with the approved starting dose or the approved method of adjustment may not be used either. If a drug is approved for twice-daily administration and the material presents only the results of a three-times-daily trial, a gap opens between the material and the approved dosage. The reader is left to bridge that gap unaided, and the information has not been "communicated accurately."
Dose-finding trials
A trial that includes off-label dose groups must be labeled "dose-finding trial," with the approved dosage noted. This lets the reader see which part of the data underlies the approval and which lies outside it. The answer is not to hide the data, but to mark its position — that is how the boundary of the approval is preserved.
03Medium neutrality — electronic materials must meet the same standard as paper
When information is provided via electronic medium, it must be prepared so that healthcare professionals understand the content as clearly as they would from paper. This sounds self-evident; in practice it identifies a specific trap.
The latitude that electronic media allow
Electronic materials can expand content on click, nest information in layered menus, and switch displays dynamically. These features are useful for organizing information — but they also make it technically possible to place information that the reader must see without fail, such as restrictive wording or dosage ceilings, behind interactions that the reader might never perform.
The Guide frames this not as a question about the medium but as a question about comprehensibility. If information that is required to be visible on paper ends up in a location that requires navigation to reach, then the electronic material has not functioned as a genuine substitute for paper. "Visible" and "findable with effort" are not the same standard.
The container changes; the quality of supplementation does not
The product information summary is the container through which the package insert is supplemented. When the container changes from paper to electronic, the scope of information it must carry and the quality with which that information reaches healthcare professionals do not change. This connects directly to the foreword's phrase "inform accurately without misleading." Just as rules on point size and framing in print materials address the gap between "included" and "communicated," the medium-neutrality requirement for electronic materials closes the same gap in a different setting.
In an electronic material, if restrictive wording on an indication is not visible without scrolling or clicking, that presentation does not meet the same standard of comprehensibility as paper. The convenience of electronic media may be used to improve layout. It may not be used to reduce the visibility of approved content.
Copy restrictive wording condition and all. Observe the ceiling on dosage. Keep comprehensibility equal regardless of medium. The three rules are not independent provisions — they are derived from one requirement: reproduce approved facts accurately. The minimum condition for a product information summary to be a supplement is that it delivers the approved content, no more and no less, to the same standard of precision in every medium. The moment restrictive wording is dropped, the moment results above the dosage ceiling are placed alongside approved data, the moment a layout is chosen that buries required content behind a click, supplementation becomes deviation.